Skip to main content

Advertisement

SpringerLink
Log in

Overview of new treatments for breast cancer

  • Minisymposium
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Progress in the treatment of breast cancer developed along multiple directions of research during the last decade. The concept of dose-intensity was addressed through retrospective analyses and prospective randomized trials. It was confirmed that dose-intensity correlates with higher response rates, but the effect of dose-intensive treatments on survival still needs to be established.

Several new cytotoxic drugs have appeared during the last several years. Taxol, navelbine, and anthrapyrazole CI-941 have been found to have major efficacy against breast cancer, with response rates exceeding 50%. Amonafide, lonidamine, and elliptinium analogs were also shown to be effective, although to a lesser degree. Antiestrogen analogs, new aromatase inhibitors, and LHRH analogs are recent developments that are changing the face of hormonal therapy.

Monoclonal antibodies are being developed and evaluated for tumor imaging applications and as vehicles for specific antitumor agents (cytotoxics, radioisotopes, and toxins). Expanding knowledge about the basic biology of breast cancer has led to the identification of growth factors and their receptors, which may be exploited for therapeutic purposes in the not too distant future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10–15, 1981.

    PubMed  Google Scholar 

  2. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552–1562, 1979.

    PubMed  Google Scholar 

  3. Henderson IC, Hayes DF, Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501–1515, 1988.

    PubMed  Google Scholar 

  4. Forastiere AA, Hakes TB, Wittes JT, Wittes RE: Cisplatin in the treatment of metastatic breast carcinoma. A prospective randomized trial of two dosage schedules. Am J Clin Oncol 5:243–247, 1982.

    PubMed  Google Scholar 

  5. Carmo-Pereira J, Costa FO, Henriques E, et al: A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56:471–473, 1987.

    PubMed  Google Scholar 

  6. Tormey DC, Gelman R, Band PR, et al: Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 50:1235–1244, 1982.

    PubMed  Google Scholar 

  7. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377–1387, 1988.

    PubMed  Google Scholar 

  8. Focan C, Closon M Th, Andrien JM, et al: Doseresponse relationship with epirubicin as neoadjuvant chemotherapy for advanced breast cancer. End results of a prospective randomized trial. Abstracts, Third International Congress on Neo-adjuvant Chemotherapy, Feb 6–9, 1991, Paris, France, Abst B29, p 17.

  9. Habeshaw T, Jones R, Stallard S, et al: Epirubicin at 2 dose levels with prednisolone as treatment for advanced breast cancer: results of a randomised trial. Proc Am Soc Clin Oncol 9:43 (Abst 163), 1990.

    Google Scholar 

  10. Becher R, Wandl U, Kloke O, et al: Randomized study of different doses of epirubicin and identical doses of cyclophosphamide in advanced breast cancer. Proc Am Soc Clin Oncol 9:46, 1990.

    Google Scholar 

  11. Hortobagyi GN, Bodey GP, Buzdar AU, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5:354–364, 1987.

    PubMed  Google Scholar 

  12. Spitzer G, Dicke K, Zander AR, et al: High-dose chemotherapy with autologous bone marrow transplantation. Cancer 54:1216–1255, 1984.

    PubMed  Google Scholar 

  13. Antman K, Gale RP: Advanced breast cancer: Highdose chemotherapy and bone marrow autotransplants. Ann Intern Med 108:570–574, 1988.

    PubMed  Google Scholar 

  14. Eder JP, Antman K, Peters W, et al: High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4:1592–1597, 1986.

    PubMed  Google Scholar 

  15. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368–1376, 1988.

    PubMed  Google Scholar 

  16. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen-receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207–1216, 1990.

    PubMed  Google Scholar 

  17. Peters WP, Jones RB, Shpall EJ, Shogan J: Dose intensification using high-dose combination alkylating agents and autologous bone marrow support for the treatment of breast cancer.In Dicke KA, Spitzer G, Jagganath S, Evinger-Hodges MJ (eds) Autologous Bone Marrow Transplantation. The University of Texas M.D. Anderson Cancer Center, Houston, 1989, pp. 389–397.

    Google Scholar 

  18. Peters WP, Davis R, Shpall EJ, et al: Adjuvant chemotherapy involving high-dose combination cyclophosphamide, cisplatin and carmustine and autologous bone marrow support for stage II/III breast cancer involving ten or more lymph nodes (CALGB 8782): a preliminary report. Proc Am Soc Clin Oncol 9:22 (Abst 80), 1990.

    Google Scholar 

  19. Gisselbrecht C, Lepage E, Extra JM, et al: Inflammatory and metastatic breast cancer: cyclophosphamide and total body irradiation with autologous bone marrow transplantation.In Dicke KA, Spitzer G, Jagganath S, Evinger-Hodges MJ (eds) Autologous Bone Marrow Transplantation. The University of Texas M.D. Anderson Cancer Center, Houston, 1989, pp. 363–366.

    Google Scholar 

  20. Mulder NH, Sleijfer DT, de Vries EGE, Willemse PHB: Intensive induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with stage IIIB and IV breast cancer. Proc Am Soc Clin Oncol 7:8 (Abst 26), 1988.

    Google Scholar 

  21. Bonadonna G: Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7:1380–1397, 1989.

    PubMed  Google Scholar 

  22. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422, 1988.

    PubMed  Google Scholar 

  23. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant human granulocyte-macrophage colonystimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593–598, 1988.

    PubMed  Google Scholar 

  24. Miller CB, Jones RJ, Piantadosi S, et al: Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 322:1689–1692, 1990.

    PubMed  Google Scholar 

  25. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colonystimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869–876, 1988.

    PubMed  Google Scholar 

  26. Cros S, Wright M, Morimoto M, et al: Experimental antitumor activity of Navelbine. Semin Oncol 16 (Suppl 4): 15–20, 1989.

    PubMed  Google Scholar 

  27. Besenval M, Delgado M, Demarez JP, Krikorian A: Safety and tolerance of Navelbine in phase I-II clinical Studies. Semin Oncol 16 (Suppl 4):37–40, 1989.

    PubMed  Google Scholar 

  28. Tresca P, Fumoleau P, Roche H, et al: Vinorelbine, a new active drug in breast carcinoma: results of an ARTAC phase II trial. Abstracts, Navelbine Satellite Symposium, 13th Annual San Antonio Breast Cancer Symposium, Nov 1–3, 1990, pp. 3.

  29. Delozier T, Delgado FM, Fumoleau, et al: Phase II trial with Navelbine in advanced breast cancer. Eur J Cancer 27 (Suppl 2):S64 (Abst 359), 1991.

    Google Scholar 

  30. Diaz-Rubio E, Lluch A, Martin M, et al: Navelbine, etude espagnole dans les cancers du sein avances. Traitement de premiere ligne. Abstracts, Third International Congress on Neoadjuvant Chemotherapy, Feb 6–9, 1991, Paris, France, Abst C8, p. 20.

  31. Bruno S, Mickiewicz E, Fernandez O, et al: Phase II trial of Navelbine in advanced breast cancer patients. Abstracts, Third International Congress on Neoadjuvant Chemotherapy, Feb 6–9, 1991, Paris, France, Abst C7, p.20.

  32. Depierre A, Lemarie E, Dabouis G, et al: Efficacy of Navelbine in non-small cell lung cancer. Semin Oncol 16 (Suppl 4):26–29, 1989.

    PubMed  Google Scholar 

  33. George MJ, Heron JF, Kerbrat P, et al: Navelbine in advanced ovarian epithelial cancer: A study of the french oncology centers. Semin Oncol 16 (Suppl 4):30–32, 1989.

    Google Scholar 

  34. Armand JP, Marty M: Navelbine: A new step in cancer therapy. Semin Oncol 16 (Suppl 4):41–45, 1989.

    Google Scholar 

  35. Dieras V, Extra JM, Bellissant E, et al: Study of Navelbine and fluorouracil in advanced breast cancer patients with a group sequential design. Eur J Cancer 27 (Suppl 2):S60 (Abst 334).

  36. Spielmann M, Jouve M, Turpin F, et al: Navelbine-Adriamycin combination in 1st line chemotherapy treatment in advanced breast cancer. Results of a phase II study. Abstracts, Third International Congress of Neoadjuvant Chemotherapy, Feb 6–9, 1991, Paris, France, Abst C1, p.18.

  37. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247–1259, 1990.

    PubMed  Google Scholar 

  38. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83:1797–1805, 1991.

    PubMed  Google Scholar 

  39. Smith IE, Talbot DC, Mansi JL, et al: Anthrapyrazole CI-941: a highly active new drug against advanced breast cancer. Proc Am Soc Clin Oncol 10:55 (Abst 94), 1991.

    Google Scholar 

  40. Band PR, Maroun J, Pritchard K, et al: Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada clinical trials group study. Cancer Treat Rep 70:1305–1310, 1986.

    PubMed  Google Scholar 

  41. Rosso R, Amoroso D, Gardin G, et al: Lonidamine in metastatic breast cancer. Semin Oncol 18 (Suppl 4):62–65, 1991.

    Google Scholar 

  42. Legha SS, Ring S, Raber M, et al: Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 71:1165–1169, 1987.

    PubMed  Google Scholar 

  43. Dittrich C, Scheithauer W, Liebhard A, et al: Amonafide as salvage treatment in advanced breast cancer. Eur J Cancer 27 (Suppl 2):S67 (Abst 374), 1991.

    Google Scholar 

  44. Allen SL, Ratain M, Korzun AH, et al: Phase II study of amonafide in previously treated metastatic breast cancer (CALGB 8841). Proc Am Assoc Cancer Res 32:183 (Abst 1092), 1991.

    Google Scholar 

  45. Costanza ME, Korzun AH, Henderson IC, et al: Amonafide: an active agent in metastatic breast cancer (CALGB 8642). Proc Am Soc Clin Oncol 9:31 (Abst 117), 1990.

    Google Scholar 

  46. Yap HY, Buzdar AU, Hortobagyi G, et al: Promising new agents for metastatic breast cancer.In Ames FC, Blumenschein GR, Montague ED (eds) Current Controversies in Breast Cancer. University of Texas Press, Austin, 1984, pp 283–290.

    Google Scholar 

  47. Rouesse JG, Le Chevalier T, Caille P, et al: Phase II study of elliptinium in advanced breast cancer. Cancer Treat Rep 69:707–708, 1985.

    PubMed  Google Scholar 

  48. Buzdar AU, Hortobagyi GN, Esparza LT, et al: Elliptinium acetate in metastatic breast cancer — a phase II study. Oncology 47:101–104, 1990.

    PubMed  Google Scholar 

  49. Gad-el-Mawla N: Trials with ifosfamide in malignancy. Proc Intl Holoxan Symp, Dusseldorf, Mar 21–23, 1977, pp. 107–108.

  50. Ahmann DL, Bisel HF, Hahn RG: Phase II clinical trial of isophosphamide in patients with advanced breast cancer. Cancer Chemother Rep 58:861–865, 1974.

    PubMed  Google Scholar 

  51. Falkson G, Falkson HC: Further experience with isophosphamide. Cancer Treat Rep 60:955–957, 1976.

    PubMed  Google Scholar 

  52. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811–1814, 1988.

    PubMed  Google Scholar 

  53. Kolaric K, Roth A: Phase II clinical trial of cisdichlorodiammine platinum for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108–112, 1983.

    PubMed  Google Scholar 

  54. Legha SS: Tamoxifen in the treatment of breast cancer. Ann Intern Med 109:219–228, 1988.

    PubMed  Google Scholar 

  55. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 319:1681–1692, 1988.

    Google Scholar 

  56. Fisher B, Redmond C: New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. JNCI 83:1278–1280, 1991.

    PubMed  Google Scholar 

  57. Love RR, Mazess RB, Tormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297–301, 1988.

    PubMed  Google Scholar 

  58. Love RR, Newcomb PA, Wiebe DL, et al: Lipid and lipoprotein effects of tamoxifen therapy in postmenopausal women with node-negative breast cancer. JNCI 82:1327–1332, 1990.

    PubMed  Google Scholar 

  59. Santen RJ, Misbin RI: Aminoglutethimide: Review of pharmacology and clinical use. Pharmacother 1:95–120, 1981.

    Google Scholar 

  60. Goss PE, Powles TJ, Dowsett M, et al: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Res 46:4823–4826, 1986.

    PubMed  Google Scholar 

  61. Sawka CA, Pritchard KI, Paterson AHG, et al: Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 46:3152–3156, 1986.

    PubMed  Google Scholar 

  62. Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA: LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23:867–873, 1985.

    PubMed  Google Scholar 

  63. Kaufmann M: Zoladex in the treatment of premenopausal metastatic breast cancer patients. Horm Res 32 (Suppl 1):202–205, 1989.

    PubMed  Google Scholar 

  64. Hoffken K, Oesterdickhoff C, Becher R, et al: LH-RH agonist treatment with buserelin in premenopausal patients with advanced breast cancer: a phase II study. Cancer Therapy and Control 1:13–20, 1989.

    Google Scholar 

  65. Lippman ME, Dickson RB: Growth control of normal and malignant epithelium.In Ragaz J, Simpson-Herren L, Lippman ME, Fisher B (eds) Effects of Therapy on Biology and Kinetics of the Residual Tumor, Part A: Pre-clinical Aspects. Wiley-Liss, New York, 1990, pp 147–178.

    Google Scholar 

  66. Osborne CK, Arteaga CL: Autocrine and paracrine growth regulation of breast cancer: Clinical implications. Breast Cancer Res Treat 15:3–11, 1990.

    PubMed  Google Scholar 

  67. Ervin PR, Kaminski MS, Cody RL, Wicha MS: Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science 244:1585–1587, 1989.

    PubMed  Google Scholar 

  68. Quesada JR, Reuben J, Manning JT, et al: Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18, 1984.

    PubMed  Google Scholar 

  69. Sosman JA, Kohler PC, Hank J, et al: Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. JNCI 80:60–63, 1988.

    PubMed  Google Scholar 

  70. Lamki LM, Buzdar AU, Singletary SE, et al: Indium-111-labeled B 72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 32:1326–1332, 1991.

    PubMed  Google Scholar 

  71. Ceriani RL, Thompson K, Peterson JA, Abraham S: Surface differentiation antigens on human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci USA 74:582–586, 1977.

    PubMed  Google Scholar 

  72. Johnson VG, Schlom J, Paterson AJ, et al: Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 46:850–857, 1986.

    PubMed  Google Scholar 

  73. Burchell J, Gendler S, Taylor-Papadimitriou J, et al: Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 47: 5476–5482, 1987.

    PubMed  Google Scholar 

  74. Schlom J, Molinolo A, Simpson JF, et al: Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. JNCI 82:763–771, 1990.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Gabriel N. Hortobagyi M.D., F.A.C.P.

Authors
  1. Gabriel N. Hortobagyi M.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Held at the 14th Annual San Antonio Breast Cancer Symposium, December 5, 1991, and supported by an educational grant from Bristol-Myers Oncology Division, Evansville IN, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hortobagyi, G.N. Overview of new treatments for breast cancer. Breast Cancer Res Tr 21, 3–13 (1992). https://doi.org/10.1007/BF01811959

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01811959

Key words

Search

Navigation